Achieve Life Sciences (STU:SP4P) E10: €-188.15 (As of Mar. 2026)


STU:SP4P Achieve Life Sciences Inc STU:SP4P
32 GF Score
Price €5.35
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences E10?

Achieve Life Sciences STU:SP4P -3.60% 32 E10 is €-188.15 as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Achieve Life Sciences's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.164. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-188.15 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 44.10% per year. During the past 5 years, the average E10 Growth Rate was 35.20% per year. During the past 10 years, the average E10 Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Achieve Life Sciences was 44.10% per year. The lowest was -10.20% per year. And the median was 17.25% per year.

As of today (2026-07-12), Achieve Life Sciences's current stock price is €5.35. Achieve Life Sciences's E10 for the quarter that ended in Mar. 2026 was €-188.15. Achieve Life Sciences's Shiller PE Ratio of today is .


Achieve Life Sciences  (STU:SP4P) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Achieve Life Sciences E10 Related Terms


Achieve Life Sciences E10 Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences E10 Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,488.79 -1,367.58 -767.55 -428.86 -185.51

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -357.33 -252.28 -217.02 -185.51 -188.15

STU:SP4P vs STTK, CRMD, EIKN: E10 Comparison

For the Biotechnology subindustry, Achieve Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Shiller PE Ratio falls into.


STU:SP4P
32GF Score
Achieve Life Sciences Inc STU:SP4P
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Achieve Life Sciences's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.164/330.2130*330.2130
=-0.164

Current CPI (Mar. 2026) = 330.2130.

Achieve Life Sciences Quarterly Data

per share eps CPI Adj_EPS
201606 -450.340 241.018 -617.000
201609 -235.224 241.428 -321.727
201612 -396.264 241.432 -541.981
201703 -14.015 243.801 -18.982
201706 -10.797 244.955 -14.555
201709 -150.349 246.819 -201.148
201712 -52.902 246.524 -70.861
201803 -39.415 249.554 -52.154
201806 -31.158 251.989 -40.830
201809 -12.169 252.439 -15.918
201812 -9.669 251.233 -12.709
201903 -15.576 254.202 -20.234
201906 -8.921 256.143 -11.501
201909 -8.236 256.759 -10.592
201912 -5.400 256.974 -6.939
202003 -1.946 258.115 -2.490
202006 -1.492 257.797 -1.911
202009 -0.968 260.280 -1.228
202012 -0.635 260.474 -0.805
202103 -1.092 264.877 -1.361
202106 -1.270 271.696 -1.544
202109 -0.604 274.310 -0.727
202112 -0.673 278.802 -0.797
202203 -0.726 287.504 -0.834
202206 -1.022 296.311 -1.139
202209 -1.364 296.808 -1.518
202212 -0.784 296.797 -0.872
202303 -0.467 301.836 -0.511
202306 -0.397 305.109 -0.430
202309 -0.319 307.789 -0.342
202312 -0.220 306.746 -0.237
202403 -0.239 312.332 -0.253
202406 -0.232 314.175 -0.244
202409 -0.324 315.301 -0.339
202412 -0.344 315.605 -0.360
202503 -0.342 319.799 -0.353
202506 -0.321 322.561 -0.329
202509 -0.239 324.800 -0.243
202512 -0.239 324.054 -0.244
202603 -0.164 330.213 -0.164

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-188.15 mean?
Achieve Life Sciences (STU:SP4P) has a E10 of €-188.15 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Achieve Life Sciences and its competitors.
Is Achieve Life Sciences' E10 too high?
Achieve Life Sciences' current E10 is €-188.15. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' E10 compare to STTK and CRMD?
Achieve Life Sciences' E10 of €-188.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current E10 is €-188.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current E10 of €-188.15. The current E10 is €-188.15. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current E10 is €-188.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score

Get the complete analysis for STU:SP4P

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.35
Price